Author:
Parinandi Narasimham L.,Liaugminas Alex,Oliver Patrick J.,Varadharaj Saradhadevi,Yenigalla Anita,Elliott Austin C.,Arutla Sukruthi,Campbell Steven J.,Kotha Sainath R.,Sherwani Shariq I.,Kutala Vijay K.,McDaniel Jodi C.,Maddipati Krishna Rao,Kuppusamy Periannan,Hund Thomas J.
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Biochemistry,General Medicine,Biophysics
Reference112 articles.
1. Whitman, S., Gezginci, M., Timmermann, B. N. & Holman, T. R. (2002). Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase. Journal of Medicinal Chemistry, 45, 2659–2661.
2. Avis, I. M., Jett, M., Boyle, T., Vos, M. D., Moody, T., Treston, A. M., Martinez, A. & Mulshine, J. L. (1996). Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. The Journal of Clinical Investigation, 97(3), 806–813.
3. Steele, V. E., Holmes, C. A., Hawk, E. T., Kopelovich, L., Lubet, R. A., Crowell, J. A., Sigman, C. C., & Kelloff, G. J. (1999). Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiology, Biomarkers & Prevention, 8, 467–483.
4. Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A., & Serhan, C. N. (1987). Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science, 237(4819), 1171–1176.
5. Dailey, L. A. & Imming, P. (1999). 12-lipoxygenase: classification, possible therapeutic benefits from inhibition, and inhibitors. Current Medicinal Chemistry, 6(5), 389–398.